Loss of epigenetic regulation disrupts lineage integrity, reactivates multipotency and promotes breast cancer

Ellen Langille, Khalid N. Al‐Zahrani, Zhibo Ma, Ahmad Malik, Sampath K. Loganathan, Dan Trcka, Jeff Liu, Katelyn J. Kozma, Ricky Tsai, Katie Teng, Roderic Espín, Seda Barutcu, Thomas Nguyen, Rod Bremner, Hartland W. Jackson, Erik S. Knudsen, Gary D. Bader, Sean E. Egan, Miguel Ángel Pujana, Jeffrey L. Wrana, Geoffrey M. Wahl, Daniel SchramekbioRxiv 2021 · DOI

Abstract

Systematically discerning functional drivers from inconsequential "passenger" mutations is a central challenge in cancer genomics. Using a somatic in vivo CRISPR/Cas9 mutagenesis screen, we investigated 215 recurrently mutated "long-tail" breast cancer genes. Our findings reveal that epigenetic regulation is a major tumor-suppressive mechanism. Specifically, loss of core components of the COMPASS histone methylase complex—including KMT2C, KDM6A, BAP1, and ASXL2 (collectively termed "EpiDrivers")—cooperates with the common PIK3CA H1047R mutation to accelerate tumorigenesis. This process is driven by "lactation mimicry," where cells lose their lineage integrity and reactivate a multipotent, alveolar-like program normally reserved for pregnancy. Given that these EpiDrivers are altered in 39% of human breast cancers, this mechanism represents a significant pathway in early disease progression.

Introduction: The "Long-Tail" Challenge

Breast cancer genomics is characterized by a few highly frequent mutations, such as TP53 and PIK3CA, followed by a "long tail" of hundreds of genes mutated in only 2–10% of patients. Determining which of these rare mutations are true drivers of cancer has historically been slow and resource-intensive. Furthermore, the functional consequences of these mutations on cellular identity—or lineage integrity—have remained largely unexplored. If a cell "forgets" its specific identity (e.g., whether it is a basal or luminal cell), it may become more plastic and susceptible to oncogenic transformation.

Systematic Discovery via In Vivo CRISPR Screening

To address this, we developed a high-throughput somatic in vivo CRISPR/Cas9 screen. Rather than relying on traditional in vitro models, we injected a library of 860 sgRNAs targeting 215 "long-tail" genes directly into the mammary glands of mice carrying a latent Pik3ca H1047R mutation. This approach allowed us to observe tumor development in a native physiological environment.

To analyze the resulting tumors, we employed a multi-omic approach:

  • Single-cell Multi-omics: Combining scRNA-seq and snATAC-seq to map the transcriptomic and epigenetic landscape of early-stage transformation.
  • Lineage Tracing: Utilizing viral vectors (Ad-K5-Cre and Ad-K8-Cre) to track whether tumors originated from basal or luminal cell populations.
  • Human Validation: Validating findings using CRISPR knockouts in human MCF10A mammary cells and analyzing clinical data from the METABRIC and TCGA datasets.

The COMPASS Complex and "EpiDrivers"

The screen identified a cluster of genes that, when lost, significantly accelerated tumor growth. These genes—KMT2C, KDM6A, BAP1, and ASXL2—are all involved in the COMPASS histone methylase complex. This complex acts as a master epigenetic regulator, controlling the "openness" of chromatin and the accessibility of specific genetic programs.

We found that while these genes are individually rare, they are collectively altered in approximately 39% of human breast cancers. In mice, the combination of a Pik3ca mutation and an EpiDriver knockout reduced the median time to tumor formation from 154 days to just 74 days.

Lactation Mimicry: A Hijacked Developmental Program

The most striking mechanistic finding was the activation of "lactation mimicry." In the absence of these epigenetic regulators, mammary cells began expressing milk proteins (such as Caseins and Wap) and following a genetic program typically seen during pregnancy and lactation—even in virgin mice.

This is not merely a change in gene expression; it is a functional shift. The lactation program involves a massive proliferative burst intended to prepare the mammary gland for milk production. Cancer cells hijack this rapid growth phase to drive tumor progression. Epigenetic mapping (snATAC-seq) revealed that the loss of KDM6A led to increased chromatin accessibility at sites controlled by Elf5, the master transcription factor for alveolar cell fate.

Lineage Infidelity and the Basal Origin of Luminal Tumors

The study also highlights the role of "lineage infidelity." We observed that the loss of EpiDrivers caused basal cells to adopt luminal-like characteristics and eventually form luminal-like tumors. This suggests that a significant portion of human luminal breast cancers may actually originate from basal cells that have lost their lineage integrity due to epigenetic disruption. This plasticity allows cells to bypass normal developmental constraints, reactivating multipotency to fuel malignancy.

Clinical Significance and Future Directions

The clinical implications are profound. Patients harboring both an EpiDriver mutation and high PI3K signaling exhibit the poorest survival outcomes across all breast cancer subtypes. Furthermore, the discovery that even "shallow" deletions (haploinsufficiency) of genes like KDM6A can drive poor outcomes suggests that these epigenetic regulators are highly dosage-sensitive.

Future research must determine if these epigenetic states are reversible. If we can develop therapies—such as BET inhibitors or other epigenetic modifiers—that restore the COMPASS complex's function or suppress the hijacked Elf5 program, we may be able to "re-program" these cells back to their original identities and halt tumor progression. Understanding the metabolic requirements of cells in this pseudo-lactating state may also reveal new therapeutic vulnerabilities.

Summary updated

Abstract

Abstract Systematically investigating the scores of genes mutated in cancer and discerning real drivers from inconsequential bystanders is a prerequisite for Precision Medicine, but remains challenging. Here, we developed a somatic CRISPR/Cas9 mutagenesis screen to study 215 recurrent ‘long-tail’ breast cancer genes, which revealed epigenetic regulation as major tumor suppressive mechanism. We report that core or accessory components of the COMPASS histone methylase complex including KMT2C , KDM6A , BAP1 and ASXL2 (“EpiDrivers”) cooperate with PIK3CA H1047R to transform mouse and human breast epithelial cells. Mechanistically, we find that Cre-mediated activation of PIK3CA H1047R elicited an aberrant alveolar lactation program in luminal cells, which was exacerbated upon loss of EpiDrivers. Remarkably, EpiDriver loss in basal cells also triggered an alveolar-like lineage conversion and accelerated formation of luminal-like tumors, suggesting a basal origin for luminal tumors. As EpiDrivers are mutated in 39% of human breast cancers, lineage infidelity and lactation mimicry may significantly contribute to early steps of breast cancer progression. Statement of significance Infrequently mutated genes comprise most of the mutational burden in breast tumors but are poorly understood. In-vivo CRISPR screening identified functional tumor suppressors that converged on epigenetic regulation. Loss of epigenetic regulators accelerated tumorigenesis and revealed lineage infidelity and aberrant expression of lactation genes as potential early events in tumorigenesis.
BibTeX
@misc{langille2021loss,
  author = {Ellen Langille and Khalid N. Al‐Zahrani and Zhibo Ma and Ahmad Malik and Sampath K. Loganathan and Dan Trcka and Jeff Liu and Katelyn J. Kozma and Ricky Tsai and Katie Teng and Roderic Espín and Seda Barutcu and Thomas Nguyen and Rod Bremner and Hartland W. Jackson and Erik S. Knudsen and Gary D. Bader and Sean E. Egan and Miguel Ángel Pujana and Jeffrey L. Wrana and Geoffrey M. Wahl and Daniel Schramek},
  title = {{Loss of epigenetic regulation disrupts lineage integrity, reactivates multipotency and promotes breast cancer}},
  year = {2021},
  doi = {10.1101/2021.10.22.465428},
  howpublished = {bioRxiv},
}
Figure